Eigen Therapeutics is focused on addressing tumor heterogeneity through the development of innovative combination therapies. Their approach enhances the effectiveness of targeted therapies, such as CAR T-cell therapies and antibody-drug conjugates, which are often limited by varying target levels in cancer cells. By creating co-therapies that specifically mark cancer cells while sparing healthy cells, Eigen aims to improve patient eligibility for treatment and reduce the risk of relapse. This strategy is designed to optimize therapeutic outcomes and minimize side effects, ultimately making targeted therapies more accessible to a broader range of cancer patients.

To support their mission, Eigen has developed a sophisticated platform that leverages machine learning and automation for drug discovery. Their discovery engine employs high-throughput combinatorial screening and complex phenotypic workflows to create realistic in vitro models, allowing for the rapid identification of promising therapies. The integration of robotics and custom-developed software streamlines laboratory operations, enabling scientists to conduct complex experiments efficiently. Additionally, Eigen utilizes advanced machine learning models and a comprehensive heterogeneity atlas to guide the discovery of effective co-therapies, showcasing their commitment to a multidisciplinary approach in tackling the challenges of cancer treatment.

United States

Eigen Therapeutics is a biotechnology company developing therapies that make cancer easier to find and eliminate. Eigen is focused on the development of 'priming' therapies that improve efficacy while reducing the toxicity of small molecule therapies.

Eigen Therapeutics

Company Details